ISRCTN47562898 https://doi.org/10.1186/ISRCTN47562898

Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older people with Down's syndrome, with and without dementia

Submission date
28/02/2005

Recruitment status
No longer recruiting

Registration date
16/05/2005

Overall study status
Completed

Last Edited
23/02/2012

Condition category
Nervous System Diseases

[X] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Marisa Lana

Contact details
King's College London
Wolfson Research Center for Age Related Diseases
Guy's Campus
London
United Kingdom
SE1 1UL
+44 (0)7810481267
lana@onetel.com

Additional identifiers

EudraCT/CTIS number

2005-000381-39

IRAS number

ClinicalTrials.gov number
NCT00240760

Secondary identifying numbers
KCL/DS/MEM/1

Study information

Scientific Title

Acronym
MEADOWS study

Study objectives
This is a prospective, fifty-two week, multicentre, randomised, double-blind, placebo-controlled parallel group clinical trial in people with Down's syndrome, age over 40 and people with Down's syndrome and/or dementia. The study is designed to evaluate the efficacy, safety and tolerability of memantine in this population.

Primary Aims:
1. Clinical: To determine the clinical efficacy of memantine versus placebo in preventing cognitive decline in people with Down's syndrome (DS). To compare the safety and tolerability of memantine versus placebo in people with Down's syndrome (DS).
2. Biochemical and pathological: To examine the ability of memantine to alter markers of disease progression in DS patients.

Secondary Aims:
1. Clinical: To determine whether memantine has, as compared with placebo, a significant positive impact on: the independent functioning level as measured by the carer-rated adaptive behavioural scale, (ABS) in adults with Down's syndrome suffering from dementia, quality of life in adults with Down's syndrome suffering from dementia.
2. Biochemical and pathological: To investigate putative markers of memantine's mechanism of action in peripheral samples from living patients with DS.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Cognitive decline and dementia in Down's syndrome

Interventions
Randomized, double blind, placebo controlled trial of Memantine versus placebo to assess the safety and efficacy of Memantine in preventing cognitive decline in adults with Down syndrome; effect of memantine on key progression disease markers of Alzheimer's disease in Down's syndrome.

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
memantine

Primary outcome measure
Comparing Memantine to placebo. Changes in performance from baseline on a neuropsychological battery of tests for people with DS focussing upon 3 cognitive areas: attention, memory and executive function (the DAME, battery).

Secondary outcome measures
Comparing Memantine to placebo:
1. Incidence of dementia (International Statistical Classification of Diseases and Related Health Problems - tenth revision [ICD-10] criteria)
2. Changes in performance from baseline on the Adaptive Behavioural Scale (ABS)
3. Changes in performance from baseline on quality of life (QOL-AD)
4. Changes in performance from baseline on Clinical Global Impression of Change
5. Changes in key biomarkers

Overall study start date
01/07/2005

Completion date

31/07/2006

Eligibility

Key inclusion criteria
People with Down's syndrome over the age of 40 and/or dementia

Participant type(s)
Patient

Age group
Adult

Sex
Not Specified

Target number of participants
180

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/07/2005

Date of final enrolment
31/07/2006

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
King's College London
London
United Kingdom
SE1 1UL

Sponsor information

Organisation
King's College London (UK)

Sponsor details
Prof Sir Graeme Catto
Vice Principal
The Principal's Office
JCMB 5.27
King's College London
57 Waterloo Road
London
United Kingdom
SE1 8WA

Sponsor type
Not defined

ROR
https://ror.org/0220mzb33

Funder(s)

Funder type
Industry

Funder Name
Lundbeck

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	11/02/2012		Yes	No